Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with Inhibitors
| Autor: | S. Miller, J.J. Hutter, H.A. Cooper, I. Warrier, M.L. Schmidt, N.L. Seibel, Steven Arkin, A. Shapiro |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Factor VII business.industry Vascular disease medicine.medical_treatment Hematology medicine.disease Surgery law.invention Central nervous system disease chemistry.chemical_compound chemistry law Physiology (medical) Anesthesia Coagulopathy Recombinant DNA Medicine Complication business Adverse effect |
| Zdroj: | Pathophysiology of Haemostasis and Thrombosis. 28:93-98 |
| ISSN: | 1424-8840 1424-8832 |
| DOI: | 10.1159/000022418 |
| Popis: | Activated recombinant human coagulation factor VII (rFVIIa) is a promising new therapeutic agent for patients with hemophilia A or B with inhibitors who experience serious bleeding episodes or who need coverage during surgical procedures. This open-label, uncontrolled, emergency-use study evaluated the efficacy and safety of rFVIIa in 11 hemophiliac patients and 1 FVII-deficient patient with life-threatening intracranial hemorrhage previously unresponsive to one or more alternative therapies. rFVIIa effectively controlled intracranial hemorrhage in 10 of the 12 patients. Patients with hemophilia A or B received an average of 96.9 rFVIIa injections over 14.7 days with a mean total administration of 153.3 mg, corresponding to 8.1 mg/kg. Most reported adverse events were considered to be unrelated to rFVIIa therapy. These findings suggest that rFVIIa is an effective and well-tolerated therapeutic option in the management of central nervous system bleeding in patients with hemophilia A or B with inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|